When Hoechst Marion Roussel pulled Seldane from the U.S. market in 1997 and the Food and Drug Administration formally withdrew its approval effective 4 November 1998, the official posture was prudent stewardship; the documented record shows the company removing a drug it had known to be conditionally lethal for at least six years, and doing so only once it had a patented, profitable substitute ready to sell. Seldane (terfenadine), synthesized by Richardson-Merrell chemists in 1973 and marketed in the United States in 1985 as the world’s first nonsedating antihistamine, was a genuine therapeutic advance: it relieved hay fever without the drowsiness that made older antihistamines hazardous to drivers and workers. That advance concealed a defect in the molecule itself.
The gap between promise and harm lay in pharmacokinetics. Terfenadine as swallowed was a prodrug, almost entirely converted by the liver enzyme CYP3A4 into an active metabolite that did the antihistamine work. The unconverted parent compound, however, blocked the hERG (Kv11.1) cardiac potassium channel, prolonging the QT interval and inviting torsades de pointes, a chaotic ventricular rhythm that can kill within minutes. So long as metabolism was brisk, parent levels stayed trivial and the heart was safe. But any common CYP3A4 inhibitor — the antifungals ketoconazole and itraconazole, the macrolide antibiotics erythromycin and clarithromycin, even a glass of grapefruit juice — could throttle that conversion, let the parent drug pile up, and convert an allergy pill into an arrhythmogen. A patient stable for years could be killed by a course of antibiotics for a sinus infection.
The verdict is therefore plain at the outset: the danger was not a late surprise but a measured, published mechanism. FDA reports flagged ventricular arrhythmias by June 1990; a boxed warning followed in July 1992; and the landmark Honig study in JAMA in March 1993 demonstrated, in healthy volunteers, that ketoconazole co-administration made parent terfenadine accumulate and the QT interval lengthen. For most of the drug’s life the response was a warning label on a product that remained on pharmacy shelves and, for a time, was even pursued for over-the-counter status.
What finally ended Seldane was not the body count but the chemistry of replacement. The active metabolite — fexofenadine — carried the antihistamine benefit without the parent compound’s hERG liability. Marion Merrell Dow’s successor patented it, the FDA approved it as Allegra in July 1996, and only then did the maker withdraw Seldane and the FDA move to revoke approval. Terfenadine became the first blockbuster pulled for QT-related arrhythmia, the case that taught regulators to screen new drugs against the hERG channel, and a byword for a harm that was understood, labeled, and tolerated until a safer money-maker was ready.
When Janssen Pharmaceutica — the Belgian unit of Johnson & Johnson — announced on 23 March 2000 that it would stop general U.S. marketing of Propulsid, it presented the move as a precaution; the documented record shows a drug the company’s own labels had flagged as potentially lethal since 1995, kept on the open market for five more years while prescriptions ran past thirty million. Propulsid (cisapride) was a gastrointestinal prokinetic approved by the U.S. Food and Drug Administration in 1993 for nighttime heartburn from gastroesophageal reflux. It worked by speeding the gut, but it also blocked a cardiac potassium channel, prolonging the QT interval and, in vulnerable patients, triggering torsades de pointes — a chaotic ventricular arrhythmia that can stop the heart.
The gap between the indication and the harm was the whole tragedy. Cisapride was approved for adult reflux, but its danger concentrated in people who should never have received it: patients taking common interacting drugs — the macrolide antibiotics erythromycin and clarithromycin, the antifungals ketoconazole, itraconazole and fluconazole — that raised cisapride’s blood levels, and patients with underlying cardiac or metabolic risk. By the FDA’s accounting, of the 341 serious arrhythmias and 80 deaths reported through December 1999, roughly 85 percent occurred in patients with a recognized contraindication or risk factor. The drug was, in effect, safe in the population that did not need protecting and dangerous in the population that did.
The verdict is therefore plain at the outset: an approved, widely prescribed heartburn pill killed through interactions its manufacturer and the FDA had named in the label years before the withdrawal, and a meaningful share of the dead were infants and children who received it off-label for colic and reflux even though it was never approved for pediatric use. One observational study of roughly 58,000 premature infants found that about a fifth had been given cisapride.
What followed was a slow regulatory unwind and a mass-tort settlement. Janssen halted general sale effective 14 July 2000, retaining only a tightly controlled limited-access protocol; in 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims that the drug caused some 300 deaths and nearly 16,000 injuries. Propulsid became the textbook case of a “Dear Doctor” letter and a black box that did not change prescribing fast enough to stop the dying.
When the U.S. Food and Drug Administration asked manufacturers to pull propoxyphene from the American market on 19 November 2010, it was retiring a painkiller that Eli Lilly had introduced in 1957 and that had been prescribed to tens of millions of people across two regulatory generations; the documented record shows the agency acted only after a study it had itself ordered proved the harm, and decades after the first petition to ban the drug was filed. Propoxyphene — marketed alone as Darvon and combined with acetaminophen as Darvocet — was promoted for half a century as a mild, well-tolerated opioid for moderate pain. The gap between that gentle reputation and the molecule’s actual pharmacology was the whole story: at or near ordinary therapeutic doses the drug prolonged the PR interval, widened the QRS complex, and lengthened the QT interval, the electrocardiographic signature of a compound that can stop a heart.
The harm was not subtle and not new. Propoxyphene blocks cardiac sodium channels more potently than the antiarrhythmic agents lidocaine, quinidine, and procainamide, and its long-lived metabolite norpropoxyphene accumulates — especially in the elderly and in patients with impaired kidneys — pushing toxic effects past the point of reversal. The consumer group Public Citizen petitioned the FDA to ban propoxyphene in 1978 and again in February 2006. The drug had been associated with more than 2,000 accidental U.S. deaths since 1981 and ranked among the most common drugs found in fatal overdoses, a mortality profile that prompted the United Kingdom to begin withdrawing the equivalent product, co-proxamol, in January 2005.
The verdict here is therefore plain at the outset: an approved, familiar, “weak” medicine reached enormous populations while the evidence that would eventually condemn it — sodium-channel data, autopsy series, decades of overdose statistics, and a foreign regulator’s reversal — sat fully legible in the literature. The thing that finally moved the FDA was not new theory but a single dedicated experiment: a controlled electrocardiographic study in healthy volunteers, completed in 2010, showing that even at labeled doses propoxyphene measurably deranged cardiac conduction.
What followed the withdrawal was less a courtroom reckoning than a public-health correction visible in the morgue. In the state of Florida, where overdose deaths are tracked closely, fatalities involving propoxyphene fell on the order of 84 percent after the drug left the market — a natural experiment that quantified, in lives, the cost of every year the agency had waited. Propoxyphene became the standard byword for regulatory delay: a case in which the question was not whether a drug was dangerous but how long an agency could decline to answer a petition it had already received twice.